MeSH tree: C14.907.454.460
Dr. Sabine Mai, Canada Research Chair in Genomic Instability and Nuclear Architecture of Cancer with the Rady Faculty of Health Sciences recently co-authored an article published in the American Journal of Hematology. The ...
Aug 9, 2024
0
49
The U.S. Food and Drug Administration has approved Johnson & Johnson's Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation ...
Aug 8, 2024
0
54
Research carried out by a group from Cima and the Clínica Universidad de Navarra has described the composition of the immune system in blood samples from patients with multiple myeloma, by generating a new immunological atlas, ...
Aug 6, 2024
0
34
CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the U.S. and a year later in Europe for treating acute lymphoblastic ...
Aug 2, 2024
0
39
A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according ...
Jul 24, 2024
0
31
Research on thousands of proteins measured from a drop of blood demonstrates the ability of proteins to predict the onset of many diverse diseases.
Jul 22, 2024
0
127
Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back.
Jul 1, 2024
0
52
In the relentless fight against cancer, a new technology promises to shed light on how we track and understand the spread of this disease within the body. A research team from Northeastern University and Dartmouth College ...
Jun 7, 2024
0
24
The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy ...
May 24, 2024
0
64
A U.S. Food and Drug Administration committee voted unanimously in April to approve a new clinical endpoint, minimal residual disease (MRD), when evaluating proposed drugs to treat multiple myeloma.
May 22, 2024
0
34
